Yingqiu Zhang

1.0k citations

31 papers · 772 indexed · h-index 15

Co-authors: Han Liu Taishu Wang Jinrui Zhang Shuyan Liu Yueguang Wu Duchuang Wang Fang Liu Mohamed Y. Zaky
Topics: Ubiquitin and proteasome pathways (10 papers)RNA modifications and cancer (4 papers)Glycosylation and Glycoproteins Research (3 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Cell Death and Differentiation Archives of Biochemistry and Biophysics European Journal of Pharmacology
Partner nations: China Egypt United States

In The Last Decade

Yingqiu Zhang

28 papers receiving 767 citations

Peers

Countries citing papers authored by Yingqiu Zhang

Since Specialization

Citations

This map shows the geographic impact of Yingqiu Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingqiu Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingqiu Zhang more than expected).

Fields of papers citing papers by Yingqiu Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingqiu Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingqiu Zhang. The network helps show where Yingqiu Zhang may publish in the future.

Co-authorship network of co-authors of Yingqiu Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yingqiu Zhang. A scholar is included among the top collaborators of Yingqiu Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingqiu Zhang. Yingqiu Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	USP39 phase separates into the nucleolus and drives lung adenocarcinoma progression by promoting GLI1 expression 2025 ·Cell Communication and Signaling ·(unknown),(unknown),Ziyi Zhang,(unknown),(unknown),Yuxin Zhou,Yinghui Yang,Yaowen Zhang,(unknown),Yingqiu Zhang,Han Liu,(unknown),Shangqian Sun,Shuyan Liu	3
2	The COX-2 Inhibitor Celecoxib Sensitizes Nasopharyngeal Carcinoma Cells to Ferroptosis 2025 ·Current Cancer Drug Targets ·Dawei Li,Shuang Guo,(unknown),Zhaoqi Liu,Tao Yu,Yingqiu Zhang	1
3	HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer 2025 ·European Journal of Pharmacology ·Yue Zhu,Peng Wang,(unknown),Jinhao Wang,(unknown),(unknown),(unknown),Yinghui Yang,(unknown),Yingqiu Zhang,Shuyan Liu,(unknown)	0
4	Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2 2025 ·Cancer Cell International ·Jinhao Wang,Yue Zhu,(unknown),Fengping Yang,Peng Wang,Ziyi Zhang,(unknown),Mengyuan Dai,(unknown),(unknown),(unknown),(unknown),(unknown),Shuyan Liu,(unknown),(unknown),Yingqiu Zhang,(unknown)	0
5	Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis 2024 ·Archives of Biochemistry and Biophysics ·(unknown),Xiuxiu Liu,Yinghui Yang,(unknown),Nan Ding,(unknown),Jinhao Wang,Mei Yang,(unknown),Xing Lin,(unknown),(unknown),Na Ta,Yingqiu Zhang,(unknown),Fang Liu,Shuyan Liu	2
6	Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth 2023 ·Open Life Sciences ·(unknown),(unknown),(unknown),Fuqiang Wang,(unknown),Yang Zhang,Yingqiu Zhang,Hui Ma,(unknown)	0
7	The deubiquitylating enzyme USP35 restricts regulated cell death to promote survival of renal clear cell carcinoma 2023 ·Cell Death and Differentiation ·Shanshan Wang,Taishu Wang,Lanjing Zhang,(unknown),Chaoqun Chen,(unknown),Fuqiang Wang,Ruilin Wang,Qingqing Zhang,(unknown),Yingqiu Zhang,Shuyan Liu,Hongqiang Qin,Quentin Liu,Han Liu	9
8	The ubiquitin-specific protease 8 antagonizes melatonin-induced endocytic degradation of MT1 receptor to promote lung adenocarcinoma growth 2022 ·Journal of Advanced Research ·Qianhui Sun,Jinrui Zhang,Xiaoxi Li,(unknown),(unknown),Dong Guo,Qingqing Zhang,Feng Sun,Feng Zhao,(unknown),Shanshan Wang,Taishu Wang,Shuyan Liu,Lijuan Zou,Yingqiu Zhang,Han Liu	10
9	PKC signal amplification suppresses non-small cell lung cancer growth by promoting p21 expression and phosphorylation 2022 ·Heliyon ·Shuyan Liu,Yayun Zhang,(unknown),Yingqiu Zhang,Han Liu,Mu‐Hua Huang,Ruoyu Wang,Faqiang Lu	3
10	Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer 2022 ·Cellular Oncology ·Shanshan Wang,Taishu Wang,(unknown),(unknown),Fang Liu,(unknown),Fuqiang Wang,Ruilin Wang,(unknown),(unknown),(unknown),Yingqiu Zhang,Han Liu,(unknown),Kang Tian,Shuyan Liu	7
11	The Anticancer Potential of Apigenin Via Immunoregulation 2020 ·Current Pharmaceutical Design ·(unknown),Mohamed Y. Zaky,(unknown),(unknown),(unknown),Yingqiu Zhang,Osama M. Ahmed,Shuyan Liu,Han Liu	30
12	The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer 2020 ·Cell Death and Differentiation ·Jinrui Zhang,Shuyan Liu,Qiong Li,Yulin Shi,Yueguang Wu,Fang Liu,Shanshan Wang,Mohamed Y. Zaky,(unknown),Qianhui Sun,Dong Guo,Taishu Wang,Yingqiu Zhang,Yang Wang,Man Li,Han Liu	38
13	USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress 2020 ·Cell Death and Disease ·Yueguang Wu,Yingqiu Zhang,Duchuang Wang,Yang Zhang,Jinrui Zhang,Yayun Zhang,Lu Xu,Taishu Wang,Shanshan Wang,Qingqing Zhang,Fang Liu,Mohamed Y. Zaky,Qiong Li,Qianhui Sun,Dong Guo,Shuyan Liu,Lijuan Zou,Qingkai Yang,Han Liu	30
14	Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer 2019 ·The International Journal of Biochemistry & Cell Biology ·Shanshan Wang,Jinrui Zhang,Taishu Wang,(unknown),Xiuxiu Liu,Yongqi Lu,(unknown),Yang Zhang,Duchuang Wang,(unknown),Yueguang Wu,(unknown),Qiong Li,Mohamed Y. Zaky,Shuyan Liu,Weijie Dong,(unknown),Kun Zou,Yingqiu Zhang	3
15	Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met 2019 ·Archives of Biochemistry and Biophysics ·Mohamed Y. Zaky,Xiuxiu Liu,Taishu Wang,Shanshan Wang,Fang Liu,Duchuang Wang,Yueguang Wu,Yang Zhang,Dong Guo,Qianhui Sun,Qiong Li,Jinrui Zhang,Yingqiu Zhang,Weijie Dong,Zhenhua Liu,Shuyan Liu,Han Liu	7
16	Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling 2019 ·Biomedicine & Pharmacotherapy ·Yue Wu,Yingqiu Zhang,Congcong Liu,Yang Zhang,Duchuang Wang,Shanshan Wang,Yueguang Wu,Fang Liu,Qiong Li,Xiuxiu Liu,Mohamed Y. Zaky,Dong Yan,Shuyan Liu	28
17	The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms 2018 ·Cell Communication and Signaling ·Taishu Wang,Jinrui Zhang,Shanshan Wang,Xiuna Sun,Duchuang Wang,(unknown),Yang Zhang,(unknown),Yue Wu,Yueguang Wu,Fang Liu,Xiuxiu Liu,Shuyan Liu,Yingqiu Zhang,Yang Wang,Lijuan Zou,Han Liu	19
18	Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects 2018 ·Journal of Experimental & Clinical Cancer Research ·(unknown),Yang Zhang,Kang Tian,Xi Chen,Rongxin Zhang,(unknown),Yueguang Wu,Duchuang Wang,Shanshan Wang,Fang Liu,Taishu Wang,Jinrui Zhang,Shuyan Liu,Yingqiu Zhang,Cai‐Xia Tu,Han Liu	147
19	Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer 2018 ·The International Journal of Biochemistry & Cell Biology ·Taishu Wang,Duchuang Wang,(unknown),Jinrui Zhang,Xiuna Sun,Yue Wu,Shanshan Wang,Yang Zhang,(unknown),(unknown),(unknown),Yueguang Wu,Fang Liu,Shuyan Liu,Yingqiu Zhang,Ting Lei,Han Liu	6
20	Heme Oxygenase and Ocular Disease: A Review of the Literature 2012 ·Current Eye Research ·Jun Zhao,(unknown),(unknown),Yingqiu Zhang,(unknown),Ding Sun	14

About Yingqiu Zhang

Yingqiu Zhang is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 31 papers that have together received 772 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (10 papers), RNA modifications and cancer (4 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Cancer Research (139 citations), Oncology (225 citations) and Molecular Biology (487 citations). Yingqiu Zhang has collaborated with scholars based in China, Egypt and United States. Frequent co-authors include Han Liu, Taishu Wang, Jinrui Zhang, Shuyan Liu, Yueguang Wu, Duchuang Wang, Fang Liu, Mohamed Y. Zaky, Shanshan Wang and Yulin Shi. Their work appears in journals such as Cell Death and Differentiation, Archives of Biochemistry and Biophysics and European Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact